Worcester-based RXi Pharmaceuticals Corp. said it will collaborate with EyeGate Pharma of Waltham to develop RNAi-based treatments for retinal disorders.
The agreement asks each company to contribute technology, expertise and resources to the effort, which is currently focused on silencing disorder-causing genes by injecting RNA compounds into the eye.
EyeGate’s technology will be used to deliver RXi’s compounds to the eye.
Once inside the eye, it is believed that the RNA compounds will access retinal cells and silence the disease-causing genes.
RXi develops drugs based on RNAi technology. RNAi seeks to treat diseases by interfering with the genes thought to trigger those diseases.
